Hannestad I, Myklebust TÅ, Fosså SD, Müller S, Aas K (2025)
Real-world implementation and guideline adherence at inclusion of active surveillance for men with prostate cancer: a population-based study from the Cancer Registry of Norway
Scand J Urol, 60, 218-225
DOI 10.2340/sju.v60.45023, PubMed 41369008

Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE (2025)
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study
Eur J Cancer, 233, 116162 (in press)
DOI 10.1016/j.ejca.2025.116162, PubMed 41365069

Wang Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, Eriksson AGZ, Eyjolfsdottir B, Van Gorp T, Baert T, Aksnes AK, Myren K, Vergote I, Bruland ØS (2025)
First experience with intraperitoneal ²²⁴Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer
Gynecol Oncol, 204, 158-164 (in press)
DOI 10.1016/j.ygyno.2025.11.018, PubMed 41349345